899 related articles for article (PubMed ID: 21878850)
1. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T
Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850
[TBL] [Abstract][Full Text] [Related]
2. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
[TBL] [Abstract][Full Text] [Related]
3. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
4. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
Pryds A; Larsen M
Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
[TBL] [Abstract][Full Text] [Related]
5. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
[TBL] [Abstract][Full Text] [Related]
7. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy.
Izumi T; Koizumi H; Maruko I; Takahashi Y; Sonoda S; Sakamoto T; Iida T
Br J Ophthalmol; 2017 Apr; 101(4):433-437. PubMed ID: 27388248
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Noh SR; Kang MS; Kim K; Kim ES; Yu SY
Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
[TBL] [Abstract][Full Text] [Related]
9. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
Goto S; Gomi F; Ueno C; Nishida K
Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
[TBL] [Abstract][Full Text] [Related]
10. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
11. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Gulkas S; Sahin O
Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
[TBL] [Abstract][Full Text] [Related]
12. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Ojima A; Sekiryu T
Retina; 2011 Sep; 31(8):1603-8. PubMed ID: 21487334
[TBL] [Abstract][Full Text] [Related]
13. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
14. [Choroidal thickness after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy].
Zeng J; Yan YY; Ding XY; Liu R; Li JQ
Zhonghua Yan Ke Za Zhi; 2013 Jun; 49(6):490-4. PubMed ID: 24119960
[TBL] [Abstract][Full Text] [Related]
15. Assessment of choroidal topographic changes by swept source optical coherence tomography after photodynamic therapy for central serous chorioretinopathy.
Razavi S; Souied EH; Cavallero E; Weber M; Querques G
Am J Ophthalmol; 2014 Apr; 157(4):852-60. PubMed ID: 24412124
[TBL] [Abstract][Full Text] [Related]
16. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
[TBL] [Abstract][Full Text] [Related]
18. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.
Koytak A; Erol K; Coskun E; Asik N; Öztürk H; Özertürk Y
Retina; 2010; 30(10):1698-703. PubMed ID: 20539254
[TBL] [Abstract][Full Text] [Related]
19. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
20. Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy.
Yang HS; Kang TG; Park H; Heo JS; Park J; Lee KS; Choi S
PLoS One; 2020; 15(1):e0227718. PubMed ID: 31929582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]